MedPath

The Relationship Among Sarcopenia, Preperitoneal Fat Thickness and Cholecystectomy

Not Applicable
Completed
Conditions
Cholecystectomy
Sarcopenia
Interventions
Diagnostic Test: sarcopenia assessment
Diagnostic Test: visceral fat thickness measurement
Registration Number
NCT06468735
Lead Sponsor
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Brief Summary

The aim of this study was to examine the relationship between sarcopenia and visceral adiposity in participants with and without cholecystectomy.

In this way, the long-term effects of cholecystectomy operations, which are commonly performed in the society and thought to be harmless, will be evaluated.

Detailed Description

Cholecystectomy is recognized as a harmless operation with low mortality and morbidity and is commonly performed worldwide. The unexplained increase in metabolic disorders such as dyslipidemia, hyperglycemia, non-alcoholic fatty liver disease (NAFLD) and sarcopenia with cholecystectomy in recent studies has led to the need for further investigation of these patients. There are very few studies investigating the relationship among sarcopenia, visceral adiposity and cholecystectomy. In previous studies, BIA or DEXA was used for sarcopenia assessment and non-US methods were used for visceral fat assessment. In our study, we aimed to determine the relationship among sarcopenia, visceral adipose tissue and cholecystectomy by using US, which is an easy, cheap and a valid/reliable method.

A total of 158 community-dwelling patients (aged between 41 to 80 years), including cholecystectomized (N=89) and non-cholecystectomized (N=69) participants from gastroenterology clinics were included.

Sarcopenia assessment The quadriceps muscle thickness (mm) was divided by the BMI to get the sonographic thigh adjustment ratio (STAR) values. Grip strength was assessed using an electronic hand dynamometer on the dominant hand side. Three measurements were obtained from the dominant hand and the maximum value was taken for the analyses. Participants in the chair stand test (CST) were instructed to rapidly rise and fall from a chair five times while keeping their arms folded across their chests. The test was repeated three times, and the mean time was recorded. Together with low STAR values (\<1.0 for females and \<1.4 for males), having low grip strength (\<19 kg for females or \<32 kg for males) and/or prolonged CST duration (≥12 seconds) were used to diagnose sarcopenia.

Intraabdominal visceral adipose tissue thickness was calculated by placing the probe 2-cm proximal to the midline of the umbilicus with minimal pressure and measuring the distance from the inner surface of the linea alba to the anterior wall of the abdominal aorta. Subcutaneous maximum fat thickness was measured from the distance between the subcutaneous tissue and the linea alba from the same point. Preperitoneal fat thickness was measured from the distal neighborhood of the xiphoid process, 1.5 cm to the right side of the widest distance between the parietal peritoneum and the linea alba. Minimum subcutaneous fat thickness was calculated as the distance measured from the distal neighborhood of the xiphoid process, measured as the shortest distance between the outer part of the linea alba and the subcutaneous fat tissue.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
158
Inclusion Criteria
  • Cholecystectomy at least 5 years ago
  • control group; those without cholecystectomy
Exclusion Criteria
  • Advanced cardiac, hepatic and renal insufficiency,
  • active malignancies (currently or within the last one year receiving radiotherapy/chemotherapy),
  • rheumatological diseases,
  • severe knee, hip and hand osteoarthritis,
  • use of any assistive device for walking,
  • neuromuscular diseases (motor neuron diseases, polyneuropathies, myasthenia gravis),
  • major depression,
  • Parkinson's disease, previous stroke, cerebellar diseases and multiple sclerosis were excluded.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
cholecystectomysarcopenia assessmentUltrasonography-guided assessment of sarcopenia and measurement of visceral, preperitoneal, subcutaneous maximum and subcutaneous minimum fat thickness in cholecystectomised participants
Controlsarcopenia assessmentUltrasonography-guided assessment of sarcopenia and measurement of visceral, preperitoneal, subcutaneous maximum and subcutaneous minimum fat thickness in participants without cholecystectomy
cholecystectomyvisceral fat thickness measurementUltrasonography-guided assessment of sarcopenia and measurement of visceral, preperitoneal, subcutaneous maximum and subcutaneous minimum fat thickness in cholecystectomised participants
Controlvisceral fat thickness measurementUltrasonography-guided assessment of sarcopenia and measurement of visceral, preperitoneal, subcutaneous maximum and subcutaneous minimum fat thickness in participants without cholecystectomy
Primary Outcome Measures
NameTimeMethod
STAR valuesthrough study completion, an average of 4 months

\<1.0 for females and \<1.4 for males Quadriceps thickness(mm) /BMI kg/m2

visceral adipose tissue thicknessthrough study completion, an average of 4 months

mm

Subcutaneous maximum fat thicknessthrough study completion, an average of 4 months

mm

Subcutaneous minimum fat thicknessthrough study completion, an average of 4 months

mm

Preperitoneal fat thicknessthrough study completion, an average of 4 months

mm

low grip strengththrough study completion, an average of 4 months

\<19 kg for females or \<32 kg for males

chair stand test durationthrough study completion, an average of 4 months

≥12 seconds

Secondary Outcome Measures
NameTimeMethod
Waist circumferencethrough study completion, an average of 4 months

cm

BMIthrough study completion, an average of 4 months

kg/m2

Trial Locations

Locations (1)

Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital

🇹🇷

Ankara, Turkey

© Copyright 2025. All Rights Reserved by MedPath